SENTRY study: using blood platelets to detect ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at changes in blood platelets to see if they can help detect ovarian cancer earlier. It is for women who have a new ovarian or pelvic mass and are about to have a biopsy or surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 21 or older.
- You have been diagnosed with an ovarian or pelvic mass (lump).
- You have not yet received any treatment for ovarian cancer (if it is cancer).
- Your doctor plans to do a biopsy or surgery to look at the mass.
- You do not have any other active cancer (except certain skin cancers or early cervical changes).
- You can give a blood sample.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether a “liquid biopsy,” a blood test, can help doctors tell apart different causes of a suspicious pelvic/ovarian mass and help with early detection. It may help avoid uncertainty before surgery by adding test results from blood along with imaging and standard markers.
This study is testing a new blood test that may help detect ovarian cancer earlier. Researchers want to see if it can tell the difference between people with ovarian cancer and those without it.
This study is testing a blood test to see if it can catch ovarian cancer early. You may be eligible if you have been recently diagnosed with ovarian cancer and haven't started treatment yet.
This study is testing a new blood test (called the EARLY panel) to see how well it can detect ovarian cancer in postmenopausal women aged 50–74. It aims to find out if the test is accurate and practical for routine screening.
This trial tests a new blood-based test (OCS) that looks for tiny particles from tumor cells to watch for cancer returning after initial treatment. It is for women with ovarian cancer whose CA125 levels were normal before starting treatment.
This study uses a custom lab test on blood (and tumor tissue) to track ovarian cancer returning and to see how well treatment is working. It may help your care team monitor changes over time, especially after certain surgeries.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.